Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
ApexOnco Front Page
Recent articles
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
